Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wasim Feroz

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Prague Medical Report|December 3, 2020
Tubercular Mastitis Mimicking as Malignancy: A Case ReportWasim Feroz, Arwah Mohammad Ali Sheikh, Vinodkumar Mugada
Nature Reviews. Clinical Oncology|March 15, 2025
Emerging importance of HER3 in tumorigenesis and cancer therapyJoan T Garrett, Salomon Tendler, Wasim Feroz, et al.
Molecular Carcinogenesis|May 16, 2024
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancerRosalin Mishra, Mary Kate Kilroy, Wasim Feroz, et al.
Cancers|December 23, 2022
HER3 Alterations in Cancer and Potential Clinical ImplicationsMary Kate Kilroy, SoYoung Park, Wasim Feroz, et al.
Carcinogenesis|August 4, 2025
Co-targeting KRASG12D and the HER family is efficacious in colorectal cancerMary Kate Kilroy-Gehret, Cecilia Wischmeier, SoYoung Park, et al.
Plos One|May 18, 2023
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancersSamar M Alanazi, Wasim Feroz, Rosalin Mishra, et al.
International Journal of Molecular Sciences|September 14, 2024
Non-Muscle Myosin II A: Friend or Foe in Cancer?Wasim Feroz, Briley SoYoung Park, Meghna Siripurapu, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Prague Medical Report|December 3, 2020
Tubercular Mastitis Mimicking as Malignancy: A Case ReportWasim Feroz, Arwah Mohammad Ali Sheikh, Vinodkumar Mugada
Nature Reviews. Clinical Oncology|March 15, 2025
Emerging importance of HER3 in tumorigenesis and cancer therapyJoan T Garrett, Salomon Tendler, Wasim Feroz, et al.
Molecular Carcinogenesis|May 16, 2024
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancerRosalin Mishra, Mary Kate Kilroy, Wasim Feroz, et al.
Cancers|December 23, 2022
HER3 Alterations in Cancer and Potential Clinical ImplicationsMary Kate Kilroy, SoYoung Park, Wasim Feroz, et al.
Carcinogenesis|August 4, 2025
Co-targeting KRASG12D and the HER family is efficacious in colorectal cancerMary Kate Kilroy-Gehret, Cecilia Wischmeier, SoYoung Park, et al.
Plos One|May 18, 2023
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancersSamar M Alanazi, Wasim Feroz, Rosalin Mishra, et al.
International Journal of Molecular Sciences|September 14, 2024
Non-Muscle Myosin II A: Friend or Foe in Cancer?Wasim Feroz, Briley SoYoung Park, Meghna Siripurapu, et al.
Pageof 1